Panel: Comparing Delivery Architectures to Match Modalities to Indication Needs
- Debate core trade-offs including tropism, immunogenicity, manufacturability, payload size, and dosing frequency across LNP, AAV, and novel options
- Determine best-fit delivery platforms for CNS, immune modulation, oncology, hepatic, and neuromuscular indications
- Address LNP partnership models that support predictable GMP supply and scalable therapeutic development